CMXC Announces Results of Preliminary Analysis of Metabolomic Assays
News Feb 27, 2015
Cell MedX Corp. has announced that it has received the first results of the analysis of metabolomic assays taken during the Phase 1 pilot clinical trial.
The pilot clinical discovery phase trial in two diabetic subjects was performed in January 2015. Its main objective was to examine the short term metabolic impact of a single treatment with e-balance technology. Additional assays are pending.
Analysis of this early data set indicates substantial changes in at least two key pathways that would correlate with improvements in glucose and lipid metabolism. These findings will inform further experimentation, including the Phase 1B clinical trial, which begins recruiting in March 2015.
The analysis of the samples was conducted by The Metabolomics Innovation Centre at the University of Alberta (“TMIC”), whose analytic and informatics toolsets and translational “omics” expertise allows for cost-effective and more accurate results of assays.
Researchers at the University of Arizona have completed the first-of-its-kind study that could aid in the treatment, diagnosis and prevention of cervical cancer by identifying cervicovaginal metabolic signatures, or "fingerprints" that distinguish patients with HPV, pre-cancerous cervical conditions and cancer.READ MORE
Regardless of how much you exercise or how balanced your diet is, controlling your weight is more brain-related than you might have thought. In a recent study, researchers show for the first time in mice that the acyl-CoA-binding protein, or ACBP, has a direct influence on the neurons that allow rodents and humans to maintain a healthy weight.READ MORE